Based on this observation, we formulated a hypothesis that PSD, in combination with paclitaxel, could be utilized to downregulate RAC3 and inhibit paclitaxel resistance in lung adenocarcinoma cells. This evidence concerns the gene RAC3 and lung adenocarcinoma.